CXCL9/MIG Antibody (49106) [Unconjugated]

Recombinant Human CXCL9/MIG (Catalog # 392-MG) chemoattracts the BaF3 mouse pro‑B cell line transfected with mouse CXCR3 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human CXCL9/MIG (0.25 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human CXCL9/MIG Monoclonal Antibody (Catalog # MAB392). The ND50 is typically 0.5-4 µg/mL.

CXCL9/MIG was detected in immersion fixed THP‑1 human acute monocytic leukemia cell line treated with IFN gamma (positive staining) and THP‑1 human acute monocytic leukemia cell line (untreated; negative staining) using Mouse Anti-Human CXCL9/MIG Monoclonal Antibody (Catalog # MAB392) at 25 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; NL007) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. Staining was performed using our protocol for Fluorescent ICC Staining of Non-adherent Cells.

• Reactivity: Hu
• Applications: WB, B/N, CyTOF-ready, ELISA(Cap), Flow, ICC/IF
• Clone: 49106
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

CXCL9/MIG Antibody (49106) [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant human CXCL9/MIG
  Thr23-Thr125
  Accession # Q07325
• Specificity: Detects human CXCL9/MIG in ELISAs and Western blots. In ELISAs, does not cross-react with recombinant mouse (rm) CXCL9, recombinant human CXCL10.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: CXCL9
• Purity Statement: Protein A or G purified from hybridoma culture supernatant
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL
  • ELISA Standard (Matched Pair)
  • Immunocytochemistry 8-25 ug/mL
  • Intracellular Staining by Flow Cytometry 2.5 ug/10^6 cells
  • Neutralization 4-20 ug/mL
  • Western Blot 1 ug/mL
• Application Notes: ELISA Detection: Human CXCL9/MIG Biotinylated Antibody (Catalog number BAF392)
  Standard: Recombinant Human CXCL9/MIG (Catalog number 392-MG)

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CXCL9/MIG Antibody (49106) [Unconjugated]

• chemokine (C-X-C motif) ligand 9
• CMK
• crg-10
• C-X-C motif chemokine 9
• CXCL9
• Gamma-interferon-induced monokine
• Humig
• MIG
• MIGSmall-inducible cytokine B9
• monokine induced by gamma interferon
• SCYB9Monokine induced by interferon-gamma

Background

CXCL9, a member of the alpha  subfamily of chemokines that lack the ELR domain, was initially identified as a lymphokine-activated gene in mouse macrophages. Human CXCL9 was subsequently cloned using mouse MIG cDNA as a probe. The CXCL9 gene is induced in macrophages and in primary glial cells of the central nervous system specifically in response to IFN-gamma . CXCL9 has been shown to be a chemoattractant for activated T-lymphocytes and TIL but not for neutrophils or monocytes. The human CXCL9 cDNA encodes a 125 amino acid (aa) residue precursor protein with a 22 aa residue signal peptide that is cleaved to yield a 103 aa residue mature protein. CXCL9 has an extended carboxy-terminus containing greater than 50% basic aa residues and is larger than most other chemokines. The carboxy-terminal residues of CXCL9 are prone to proteolytic cleavage resulting in size heterogeneity of natural and recombinant CXCL9. CXCL9 with large carboxy-terminal deletions have been shown to have diminished activity in the calcium flux assay. A chemokine receptor (CXCR3) specific for CXCL9 and IP-10 has been cloned and shown to be highly expressed in IL-2-activated T-lymphocytes. The E. coli-expressed CXCL9 preparations produced at R&D Systems have been shown to contain greater than 80% full length CXCL9.

1. Loetscher, M. et al. (1996) J. Exp. Med. 184:963.
2. Liao, F. et al. (1995) J. Exp. Med. 182:1301.
3. Vanguri, P. (1995) J. Neuroimmunol. 56:35.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for CXCL9/MIG Antibody (MAB392)(22)

Publications using MAB392

• Parween, F;Singh, SP;Kathuria, N;Zhang, HH;Ashida, S;Otaizo-Carrasquero, FA;Shamsaddini, A;Gardina, PJ;Ganesan, S;Kabat, J;Lorenzi, HA;Riley, DJ;Myers, TG;Pittaluga, S;Bielekova, B;Farber, JM; Migration arrest and transendothelial trafficking of human pathogenic-like Th17 cells are mediated by differentially positioned chemokines Nature communications 2025-02-26 [PMID: 40000641] (Immunocytochemistry, Human)
• F Parween, SP Singh, HH Zhang, N Kathuria, FA Otaizo-Car, A Shamsaddin, PJ Gardina, S Ganesan, J Kabat, HA Lorenzi, TG Myers, JM Farber Chemokine positioning determines mutually exclusive roles for their receptors in extravasation of pathogenic human T cells bioRxiv : the preprint server for biology, 2023-02-13;0(0):. 2023-02-13 [PMID: 36789428] (ICC, Human)
• Garrido-Martin EM, Mellows TWP, Clarke J et al. M1hot tumor-associated macrophages boost tissue-resident memory T cells infiltration and survival in human lung cancer J Immunother Cancer 7/1/2020 [PMID: 32699181]
• Alejandro L. Antonia, Kyle D. Gibbs, Esme D. Trahair, Kelly J. Pittman, Amelia T. Martin, Benjamin H. Schott et al. Pathogen Evasion of Chemokine Response Through Suppression of CXCL10 Frontiers in Cellular and Infection Microbiology 8/7/2019 [PMID: 31440475]
• M Pascual-Ga, E Bonfill-Te, E Planas-Rig, C Rubio-Pere, R Iurlaro, A Arias, I Cuartas, A Sala-Hojma, L Escudero, F Martínez-R, I Huber-Ruan, P Nuciforo, L Pedrosa, C Marques, I Braña, E Garralda, M Vieito, M Squatrito, E Pineda, F Graus, C Espejo, J Sahuquillo, J Tabernero, J Seoane LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy Nat Commun, 2019-06-11;10(1):2416. 2019-06-11 [PMID: 31186412] (Neutralization, Human)
• Mudan Zhang, Xu Deng, Xinmeng Guan, Lanlan Geng, Ming Fu, Binman Zhang et al. Herpes Simplex Virus Type 2 Infection-Induced Expression of CXCR3 Ligands Promotes CD4+ T Cell Migration and Is Regulated by the Viral Immediate-Early Protein ICP4 Frontiers in Immunology 12/19/2018 [PMID: 30619292]
• CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer Br J Cancer, 2016-08-04;0(0):. 2016-08-04 [PMID: 27490802] (ICC, Human)
• Ohlsson L, Hammarstrom ML, Lindmark G et al. Ectopic expression of the chemokine CXCL17 in colon cancer cells Br. J. Cancer 2/18/2016 [PMID: 26889977]
• Pinto S, Martinez-Romero A, O'Connor J, Gil-Benso R, San-Miguel T, Terradez L, Monteagudo C, Callaghan R Intracellular coexpression of CXC- and CC- chemokine receptors and their ligands in human melanoma cell lines and dynamic variations after xenotransplantation. BMC Cancer, 2014-02-22;14(0):118. 2014-02-22 [PMID: 24559071] (Flow Cytometry, Human)
• Zahn S, Rehkamper C, Kummerer BM, Ferring-Schmidt S, Bieber T, Tuting T, Wenzel J Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFN-lambda) in cutaneous lupus erythematosus. J. Invest. Dermatol., 2010-08-19;131(1):133-40. 2010-08-19 [PMID: 20720564] (IHC-P, Human)
• Blanche Ka Ki Lo, Mei Yu, David Zloty, Bryce Cowan, Jerry Shapiro, Kevin John McElwee CXCR3/Ligands Are Significantly Involved in the Tumorigenesis of Basal Cell Carcinomas The American Journal of Pathology 5/1/2010 [PMID: 20228225]
• Oo YH, Weston CJ, Lalor PF, Curbishley SM, Withers DR, Reynolds GM, Shetty S, Harki J, Shaw JC, Eksteen B, Hubscher SG, Walker LS, Adams DH Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. J. Immunol., 2010-02-17;184(6):2886-98. 2010-02-17 [PMID: 20164417] (Neutralization, Human)
• Yoon KC, Park CS, You IC, Choi HJ, Lee KH, Im SK, Park HY, Pflugfelder SC Expression of CXCL9, -10, -11, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome. Invest. Ophthalmol. Vis. Sci., 2009-10-22;51(2):643-50. 2009-10-22 [PMID: 19850844] (IHC-P, Human)
• Franciszkiewicz K, Le Floc'h A, Jalil A, Vigant F, Robert T, Vergnon I, Mackiewicz A, Benihoud K, Validire P, Chouaib S, Combadiere C, Mami-Chouaib F Intratumoral induction of CD103 triggers tumor-specific CTL function and CCR5-dependent T-cell retention. Cancer Res., 2009-07-28;69(15):6249-55. 2009-07-28 [PMID: 19638592] (ICC, Human)
• Busuttil A, Weigt SS, Keane MP, Xue YY, Palchevskiy V, Burdick MD, Huang C, Zisman DA, Fishbein M, Lynch JP, Strieter RM, Elashoff RM, Belperio JA CXCR3 ligands are augmented during the pathogenesis of pulmonary sarcoidosis. Eur. Respir. J., 2009-04-22;34(3):676-86. 2009-04-22 [PMID: 19386686] (IHC-P, Human)
• Biancotto A, Iglehart SJ, Lisco A, Vanpouille C, Grivel JC, Lurain NS, Reichelderfer PS, Margolis LB Upregulation of human cytomegalovirus by HIV type 1 in human lymphoid tissue ex vivo. AIDS Res. Hum. Retroviruses, 2008-03-01;24(3):453-62. 2008-03-01 [PMID: 18327985] (Luminex Development, Human)
• Winter D, Moser J, Kriehuber E, Wiesner C, Knobler R, Trautinger F, Bombosi P, Stingl G, Petzelbauer P, Rot A, Maurer D Down-modulation of CXCR3 surface expression and function in CD8+ T cells from cutaneous T cell lymphoma patients. J. Immunol., 2007-09-15;179(6):4272-82. 2007-09-15 [PMID: 17785868] (IHC-Fr, Immunodepletion, Human)
• Grivel JC, Elliott J, Lisco A, Biancotto A, Condack C, Shattock RJ, McGowan I, Margolis L, Anton P HIV-1 pathogenesis differs in rectosigmoid and tonsillar tissues infected ex vivo with CCR5- and CXCR4-tropic HIV-1. AIDS, 2007;21(10):1263-72. 2007 [PMID: 17545702] (Luminex Development, Human)
• Biancotto A, Grivel JC, Iglehart SJ, Vanpouille C, Lisco A, Sieg SF, Debernardo R, Garate K, Rodriguez B, Margolis LB, Lederman MM Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. Blood, 2007-02-08;109(10):4272-9. 2007-02-08 [PMID: 17289812] (Luminex Development, Human)
• Curbishley SM, Eksteen B, Gladue RP, Lalor P, Adams DH CXCR 3 activation promotes lymphocyte transendothelial migration across human hepatic endothelium under fluid flow. Am. J. Pathol., 2005-09-01;167(3):887-99. 2005-09-01 [PMID: 16127166] (IHC, Western Blot, Human)
• Suyama T, Furuya M, Nishiyama M, Kasuya Y, Kimura S, Ichikawa T, Ueda T, Nikaido T, Ito H, Ishikura H Up-regulation of the interferon gamma (IFN-gamma)-inducible chemokines IFN-inducible T-cell alpha chemoattractant and monokine induced by IFN-gamma and of their receptor CXC receptor 3 in human renal cell carcinoma. Cancer, 2005-01-15;103(2):258-67. 2005-01-15 [PMID: 15578685] (IHC-P, Human)
• Kohrgruber N, Groger M, Meraner P, Kriehuber E, Petzelbauer P, Brandt S, Stingl G, Rot A, Maurer D Plasmacytoid dendritic cell recruitment by immobilized CXCR3 ligands. J. Immunol., 2004-12-01;173(11):6592-602. 2004-12-01 [PMID: 15557149] (IHC, Human)

Bioinformatics

• Gene Symbol: CXCL9
• Uniprot:
  • Q07325()